echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Xinlitai Allisartan and Amlodipine clinical application accepted by CDE

    Xinlitai Allisartan and Amlodipine clinical application accepted by CDE

    • Last Update: 2020-10-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Drug Basics Drug Name: Alishatan ammonia chloride tablets Application matters: Domestic production of pharmaceutical registration acceptance number: CXHL 2000533 country registration classification: chemical drugs 2.3 category acceptance note: in accordance with the provisions of Article 32 of the Administrative Licensing Law of the People's Republic of China, after examination, decided to accept.
    not receive a negative or challenged opinion from the Drug Review Center within 60 days from the date of acceptance, the applicant may conduct clinical trials in accordance with the submitted plan.
    arshatan ammonia chloride tablets (project code: SAL0107) are ARB/CCB-type compound preparations, and adaptive disorders are tentatively defined as antihypertensive.
    The product will be listed, will be listed with the company's Class 1.1 anti-blood pressure drug Xinlitan (Alishatan tablets) to form a strategic synergy to expand the scope of application of Reliantan, further extend the product life cycle of Reliantan, enrich the company's cardiovascular field of innovative product pipeline.
    source: Xinlitai Enterprise Announcement.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.